Echo Therapeutics, Inc. ECTE presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during an oral presentation session on Friday, June 8 at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA.
The presentation [ADA abstract 007-OR], entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, provided data from twenty (20) adult subjects with type 1 or type 2 diabetes whose glucose levels were monitored continuously for 24 hours.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in